Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors
暂无分享,去创建一个
[1] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[2] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[3] Pamela F. Jones,et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.
[4] Harold E. Dvorak,et al. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin , 1996, The Journal of experimental medicine.
[5] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[6] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[7] P. Porter,et al. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. , 1996, The Journal of clinical investigation.
[8] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[9] J. Rossant,et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.
[10] M. Reed,et al. Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. , 1995, The American journal of pathology.
[11] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[12] K. Alitalo,et al. Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.
[13] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[14] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[15] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[16] J. Park,et al. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.
[17] Thomas N. Sato,et al. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Iwama,et al. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. , 1993, Biochemical and biophysical research communications.
[19] O. Volpert,et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.
[20] C. Disteche,et al. Isolation and characterization of the mouse thrombospondin 3 (Thbs3) gene. , 1993, Genomics.
[21] J. Lawler,et al. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family , 1993, Journal of Cell Biology.
[22] D. Heinegård,et al. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. , 1992, The Journal of biological chemistry.
[23] H. Dvorak,et al. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[24] P. Bornstein,et al. Thrombospondins: structure and regulation of expression , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] L. Leung,et al. CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction. , 1992, The Journal of biological chemistry.
[26] J. Rossant,et al. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.
[27] P. Bornstein,et al. Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. , 1992, The Journal of biological chemistry.
[28] H. Krutzsch,et al. Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Disteche,et al. Thrombospondin II: partial cDNA sequence, chromosome location, and expression of a second member of the thrombospondin gene family in humans. , 1992, Genomics.
[30] G. Viglietto,et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[31] F. W. Wolf,et al. A second, expressed thrombospondin gene (Thbs2) exists in the mouse genome. , 1991, The Journal of biological chemistry.
[32] V. Dixit,et al. Human carcinoma cells bind thrombospondin through a Mr 80,000/105,000 receptor. , 1991, Cancer research.
[33] M. Iruela-Arispe,et al. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Ingber,et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.
[35] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Moses,et al. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane , 1990, The Journal of cell biology.
[37] P. Bagavandoss,et al. Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.
[38] R. Boot-Handford,et al. Thrombospondin gene expression by endothelial cells in culture is modulated by cell proliferation, cell shape and the substratum. , 1990, The Biochemical journal.
[39] G. Tuszynski,et al. The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. , 1989, The Journal of biological chemistry.
[40] M. Höök,et al. Thrombospondin modulates focal adhesions in endothelial cells , 1989, The Journal of cell biology.
[41] N. Ferrara,et al. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.
[42] Peter J. Polverini,et al. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.
[43] R. Hynes,et al. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.
[44] H. Dvorak,et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. , 1987, Laboratory investigation; a journal of technical methods and pathology.
[45] J. Barnwell,et al. Isolation of the thrombospondin membrane receptor. , 1987, The Journal of clinical investigation.
[46] M. Takigawa,et al. A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). , 1987, Biochemistry international.
[47] J. Fiddes,et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth , 1987, Nature.
[48] P. Bornstein,et al. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[49] H. Dvorak,et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.
[50] P. Hi. Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. , 1986 .
[51] G. Giménez-Gallego,et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity , 1986 .
[52] J. Folkman,et al. Protamine is an inhibitor of angiogenesis , 1982, Nature.
[53] J. Vacanti,et al. Control of tumor growth in animals by infusion of an angiogenesis inhibitor. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[54] E. Manseau,et al. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. , 1979, Journal of the National Cancer Institute.
[55] R. Langer,et al. Isolations of a cartilage factor that inhibits tumor neovascularization. , 1976, Science.
[56] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.
[57] D. Maglione. Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .
[58] D. Mosher. Physiology of thrombospondin. , 1990, Annual review of medicine.
[59] J. Folkman,et al. Angiogenic factors. , 1987, Science.
[60] H. Peterson. Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. , 1986, Anticancer Research.